EZH2 and neoplasm: Inhibitors of EZH2 (a component of PRC2) could attenuate the downstream effects of HOTAIR-mediated gene silencing (Ahmad et al., 2024), or lead to the de-repression of tumor-suppressive miRNAs like miR-34a in human pancreatic ductal adenocarcinoma (Li et al., 2021), thereby initiating a cascade of anti-tumor and immunomodulatory effects.